Publication:
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsAbacioglu, Ufuk; Caglar, Hale B.; Yumuk, Perran F.; Akgun, Zuleyha; Atasoy, Beste M.; Sengoz, Meric
dc.date.accessioned2022-03-12T17:52:56Z
dc.date.available2022-03-12T17:52:56Z
dc.date.issued2011
dc.description.abstractThe current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical resection plus radiotherapy and concurrent temozolomide, then adjuvant temozolomide for 6 months. This has been shown to provide survival benefits; however, the prognosis for these patients remains poor, and most relapse. The objective of this prospective Phase II study was to evaluate the efficacy and tolerability of protracted, dose-dense temozolomide therapy (100 mg/m(2) for 21 consecutive days of a 28-day cycle) in patients with recurrent glioblastoma or grade 3 gliomas who had previously received standard therapy. Of the 25 patients included (median age 50 years), 20 were evaluable for radiologic response. Two patients had partial responses and 10 had stable disease (60% overall clinical benefit); 8 patients (40%) progressed after the first treatment cycle. Five patients were not assessed for radiologic response due to early clinical progression but were included in the progression-free survival (PFS) and overall survival (OS) analyses. The median follow-up time was 7 months (range, 1-14 months). The median PFS was 3 months (95% confidence interval, CI, 1.8-4.2) and the median OS was 7 months (95% CI 5.1-8.9). The 6-month PFS rate (primary endpoint) was 17.3% (95% CI 1.7-32.2) and the 1-year OS rate was 12% (95% CI -1-25). This regimen was well tolerated. The most frequent adverse event was lymphopenia (grade 3-4 in 20 patients); no opportunistic infections were reported. Treatment was discontinued due to toxicity in 2 patients (grade 4 hepatic toxicity and thrombocytopenia). These data suggest that protracted, dose-dense temozolomide had modest activity with manageable toxicity in patients with recurrent high-grade glioma previously treated with temozolomide.
dc.identifier.doi10.1007/s11060-010-0423-2
dc.identifier.eissn1573-7373
dc.identifier.issn0167-594X
dc.identifier.pubmed20878446
dc.identifier.urihttps://hdl.handle.net/11424/230434
dc.identifier.wosWOS:000291703000021
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofJOURNAL OF NEURO-ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectProtracted
dc.subjectTemozolomide
dc.subjectHigh-grade glioma
dc.subjectGlioblastoma
dc.subjectPHASE-II TRIAL
dc.subjectBEVACIZUMAB PLUS IRINOTECAN
dc.subjectNEWLY-DIAGNOSED GLIOBLASTOMA
dc.subjectNEURO-ONCOLOGIA GICNO
dc.subjectMALIGNANT GLIOMA
dc.subjectANTITUMOR IMIDAZOTETRAZINES
dc.subject1ST RELAPSE
dc.subjectO-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
dc.subjectANAPLASTIC ASTROCYTOMA
dc.subjectADJUVANT TEMOZOLOMIDE
dc.titleEfficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
dc.typearticle
dspace.entity.typePublication
local.avesis.id5558dec6-dc57-4391-b377-1b722a6beb5a
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages9
oaire.citation.endPage593
oaire.citation.issue3
oaire.citation.startPage585
oaire.citation.titleJOURNAL OF NEURO-ONCOLOGY
oaire.citation.volume103
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Collections

Research Outputs